Company intelligence / Profile preview

OMRIX Biopharmaceuticals, Inc.

Ownership: Private
Development stage: Other

Overview

OMRIX has developed several commercial products including Evicel® and EVARREST® for stopping bleeding. Their human thrombin product met all primary endpoints in Phase 3 clinical trials. They also initiated a Phase I/II clinical trial for Adhexil™ to evaluate its safety and efficacy in preventing post-operative adhesions.

Therapeutic areas: OtherHematologyImmunology
Modalities: Biosurgical productsAntibody-based productsPlasma-derived products
Industry: Biotech

Partnerships

Ethicon, Inc.

Beyond the preview

Go deeper on OMRIX Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMRIX Biopharmaceuticals, Inc..